FSSAI files three adjudication cases against Nestlé India over infant nutrition products
The food regulator has initiated cases involving promotional claims for NAN Excella Pro Stage 1 and Lactogen Pro 1, plus a follow-up formula sample found below the prescribed biotin requirement. Nestlé India shares fell nearly 3% intraday following the development.
What happened
FSSAI filed three cases against Nestle India over promotional claims for NAN Excella Pro Stage 1 and Lactogen Pro 1, and sub-standard Biotin content in a
Key facts
- 3 adjudication cases
- 3 products
- one sample below prescribed Biotin requirement
- 3% share-price decline
- 2.85% intraday fall to ₹1,332.80
- ₹1,553 52-week high
- ₹1,145.10 52-week low
- 8% one-month stock decline
- 11.5% six-month gain
- 33% five-year return
- Regulation 4(2) of FSS Foods for Infant Nutrition Regulations, 2020
- Section 3 of IMS Act, 1992
Why this matters
Any nutrition-category partnership, acquisition or portfolio review should intensify diligence on formula compliance systems, substantiation governance and regulator-facing liabilities.
What to watch
- FSSAI adjudication notices, hearing dates, final orders, penalty amounts, and any directions on withdrawal, relabelling, reformulation, or recall.
- Whether the biotin shortfall is isolated to one sample or indicates wider batch, plant, supplier, or quality-assurance exposure.
- Any expansion of scrutiny to other Nestlé infant-nutrition products, manufacturing sites, advertising channels, or prior product batches.
- Nestlé India's disclosure of sales exposure, inventory actions, distributor returns, provisions, or changes to product availability.
- Pharmacy and e-commerce listing changes, consumer complaints, pediatrician commentary, and sustained market-share movement in infant formula.
- Government or FSSAI guidance that changes permitted infant-formula claims or intensifies nutrient-testing requirements for the entire category.
- Nestlé India is likely to submit technical evidence, challenge or clarify the alleged promotional-claim breaches, and emphasize product safety and regulatory cooperation.
- The company may conduct internal audits of infant-nutrition labels, digital marketing, medical-representative materials, nutrient specifications, and batch-release controls.
- Retailers, pharmacies, and e-commerce platforms may seek updated compliance documentation and reduce visibility for affected SKUs until clarity improves.
- Competitors may avoid aggressive comparative marketing while strengthening compliance review, but could use trade promotions to capture any availability or confidence gap.
- Investors will reassess the valuation premium assigned to Nestlé India's nutrition portfolio, focusing on the potential for recurring regulatory costs rather than immediate financial penalties alone.